article thumbnail

Prefilled syringes and vaccines: Optimising parenteral packaging for the next pandemic

Pharmaceutical Technology

When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. An example is the ability of a patient suffering from venous thrombosis to perform their own injections of heparin – an anticoagulant often packaged in a prefilled syringe.

Packaging 130
article thumbnail

7 Problems with Using Borosilicate Glass to Package Drugs

Pharma Mirror

By Christopher Weikart, Chief Scientist, SiO2 Materials Science Even though drugs are meant to save lives, the primary packaging used for delivering drug therapies and vaccines may actually be putting us in danger. The post 7 Problems with Using Borosilicate Glass to Package Drugs appeared first on Pharma Mirror Magazine.

Packaging 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These programmes will include therapies and vaccines in infectious disease and oncology areas. These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. We look forward to working with the talented scientific and technical teams at Orna.”.

RNA 147
article thumbnail

UK Chancellor trumpets £650m AstraZeneca investment

pharmaphorum

A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.

article thumbnail

Biovectra to Build First mRNA Vaccine and Drug Manufacturing Plant in Canada

XTalks

Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. Additional production would be performed at other facilities for final packaging. million, respectively.

article thumbnail

Women gain ground in ?655 million frontier research funding package

Scienmag

Is “on-demand” vaccine development the only feasible option to combat unpredictable infections, such as those causing viral pandemics? How can we make patent-free and improved equivalents to existing medicines? What is the key to understanding how the collective memories and legacies of historic empires are created?

article thumbnail

Brexit could hinder access to coronavirus vaccines, says pharma group

pharmaphorum

The UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus vaccines to the population, but welcomed other measures in this week’s spending review aimed at reviving the economy after the pandemic.